This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hensley, M. L. Articles by Spriggs, D. R. Search for Related Content PubMed PubMed Citation Articles by Hensley, M. L. Articles by Spriggs, D. R. Social Bookmarking                            What's this?

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

From the Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to David R. Spriggs, MD, Memorial-Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS.

PATIENTS AND METHODS: Patients with unresectable LMS of uterine (n = 29) or other (n = 5) primary sites who did not respond to zero to two prior chemotherapy regimens were enrolled onto a phase II study of gemcitabine 900 mg/m² intravenously (IV) on days 1 and 8 plus docetaxel 100 mg/m² IV on day 8 with granulocyte colony-stimulating factor given subcutaneously on days 9 to 15, delivered every 21 days. Patients with prior pelvic radiation received 25% lower doses of both agents. Gemcitabine was delivered over 30 or 90 minutes in cycles 1 and 2 and by 90-minute infusion in all subsequent cycles. Pharmacokinetic studies assessed in vivo differences in gemcitabine concentrations with different rates of infusion.

RESULTS: Thirty-four patients (median age, 55 years; range, 32 to 74 years) have enrolled. Fourteen had received prior pelvic radiation. Sixteen of 34 patients had progressed after doxorubicin-based therapy; 18 had no prior chemotherapy. Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%). Seven patients had stable disease. Fifty percent of patients previously treated with doxorubicin responded. Hematologic toxicity was common (neutropenia: grade 3, 15%; grade 4, 6%; thrombocytopenia: grade 3, 26%; grade 4, 3%), but neutropenic fever (6%) and bleeding events (0%) were rare. The median time to progression was 5.6 months (range, 4 to 10 months).

CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-Y. Blay and A. Le Cesne Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven Oncologist, October 1, 2009; 14(10): 1013 - 1020. [Abstract] [Full Text] [PDF]

				R. G. Maki, D. R. D'Adamo, M. L. Keohan, M. Saulle, S. M. Schuetze, S. D. Undevia, M. B. Livingston, M. M. Cooney, M. L. Hensley, M. M. Mita, et al. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas J. Clin. Oncol., July 1, 2009; 27(19): 3133 - 3140. [Abstract] [Full Text] [PDF]

				Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, and S. ADACHI A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer Anticancer Res, May 1, 2009; 29(5): 1521 - 1526. [Abstract] [Full Text] [PDF]

				P. G. Casali, L. Jost, S. Sleijfer, J. Verweij, J.-Y. Blay, and On behalf of the ESMO Guidelines Working Group Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv132 - iv136. [Full Text] [PDF]

				O. Zivanovic, M. M. Leitao, A. Iasonos, L. M. Jacks, Q. Zhou, N. R. Abu-Rustum, R. A. Soslow, M. M. Juretzka, D. S. Chi, R. R. Barakat, et al. Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems J. Clin. Oncol., April 20, 2009; 27(12): 2066 - 2072. [Abstract] [Full Text] [PDF]

				D. M. Thomas, A. Gronchi, and B. O'Sullivan A Multidisciplinary Approach to Retroperitoneal Sarcomas: Current State-of-the-Art ASCO Educational Book, January 1, 2009; 2009(1): 701 - 708. [Abstract] [Full Text] [PDF]

				N. Penel, B. N. Bui, J.-O. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez, et al. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study J. Clin. Oncol., November 10, 2008; 26(32): 5269 - 5274. [Abstract] [Full Text] [PDF]

				A. W. ElBardissi, J. A. Dearani, R. C. Daly, C. J. Mullany, T. A. Orszulak, F. J. Puga, and H. V. Schaff Survival After Resection of Primary Cardiac Tumors: A 48-Year Experience Circulation, September 30, 2008; 118(14_suppl_1): S7 - S15. [Abstract] [Full Text] [PDF]

				C. Bloom Breathless beyond obvious BMJ, September 17, 2008; 337(sep17_2): a1405 - a1405. [Full Text]

				S. L. Spunt, S. X. Skapek, and C. M. Coffin Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcomas Oncologist, June 1, 2008; 13(6): 668 - 678. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				R. G. Maki Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future Oncologist, August 1, 2007; 12(8): 999 - 1006. [Abstract] [Full Text] [PDF]

				P. Lorigan, J. Verweij, Z. Papai, S. Rodenhuis, A. Le Cesne, M. G. Leahy, J. A. Radford, M. M. Van Glabbeke, A. Kirkpatrick, P. C.W. Hogendoorn, et al. Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J. Clin. Oncol., July 20, 2007; 25(21): 3144 - 3150. [Abstract] [Full Text] [PDF]

				R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno, B. Samuels, M. Fanucchi, D. C. Harmon, S. M. Schuetze, D. Reinke, et al. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 J. Clin. Oncol., July 1, 2007; 25(19): 2755 - 2763. [Abstract] [Full Text] [PDF]

				V. N Harry, G. V Narayansingh, and D. E Parkin Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls Obstet Gynaecol (Lond), April 1, 2007; 9(2): 88 - 94. [Abstract] [Full Text] [PDF]

				P. W.T. Pisters, B. O'Sullivan, and R. G. Maki Evidence-Based Recommendations for Local Therapy for Soft Tissue Sarcomas J. Clin. Oncol., March 10, 2007; 25(8): 1003 - 1008. [Abstract] [Full Text] [PDF]

				N. D. Price, J. Trent, A. K. El-Naggar, D. Cogdell, E. Taylor, K. K. Hunt, R. E. Pollock, L. Hood, I. Shmulevich, and W. Zhang Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas PNAS, February 27, 2007; 104(9): 3414 - 3419. [Abstract] [Full Text] [PDF]

				R. A. Soo, L. Z. Wang, L. S. Tham, W. P. Yong, M. Boyer, H. L. Lim, H. S. Lee, M. Millward, S. Liang, P. Beale, et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer Ann. Onc., July 1, 2006; 17(7): 1128 - 1133. [Abstract] [Full Text] [PDF]

				S. Leyvraz, M. Zweifel, G. Jundt, A. Lissoni, T. Cerny, C. Sessa, M. Fey, D. Dietrich, H. P. Honegger, and For the Swiss Group for Clinical Cancer Research ( Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas Ann. Onc., April 1, 2006; 17(4): 646 - 651. [Abstract] [Full Text] [PDF]

				S. Sleijfer, C. Seynaeve, and J. Verweij Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care Oncologist, November 1, 2005; 10(10): 833 - 841. [Abstract] [Full Text] [PDF]

				M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas Soft-Tissue Sarcomas in Adults N. Engl. J. Med., August 18, 2005; 353(7): 701 - 711. [Full Text] [PDF]

				S. Okuno, W. J. Maples, M. R. Mahoney, T. Fitch, J. Stewart, P. M. Fracasso, M. Kraut, D. S. Ettinger, F. Dawkins, and C. Erlichman Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II Consortium J. Clin. Oncol., May 1, 2005; 23(13): 3069 - 3073. [Abstract] [Full Text] [PDF]

				A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom, J. Verweij, J. Radford, P. Lorigan, S. Rodenhuis, I. Ray-Coquard, S. Bonvalot, et al. Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial J. Clin. Oncol., January 20, 2005; 23(3): 576 - 584. [Abstract] [Full Text] [PDF]

				K. M. Leu, L. J. Ostruszka, D. Shewach, M. Zalupski, V. Sondak, J. S. Biermann, J. S.-J. Lee, C. Couwlier, K. Palazzolo, and L. H. Baker Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma J. Clin. Oncol., May 1, 2004; 22(9): 1706 - 1712. [Abstract] [Full Text] [PDF]

				M. Laufer, S. Ramalingam, M. P. Schoenberg, M. E. Haisfield-Wolf, E. G. Zuhowski, I. N. Trueheart, M. A. Eisenberger, O. Nativ, and M. J. Egorin Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study J. Clin. Oncol., February 15, 2003; 21(4): 697 - 703. [Abstract] [Full Text] [PDF]